# Spatiotemporal Remodeling of Presynaptic Terminals in Human Neuromuscular Junctions

**Authors:** Zhanyang Liang, Sebastian L. Schubert, Aline Müller, Miguel Pishnamaz, Frank Hildebrand, Mahtab Nourbakhsh, Xiaoying Chen

PMC · DOI: 10.3390/ijms27041928 · International Journal of Molecular Sciences · 2026-02-17

## TL;DR

This study explores how presynaptic terminals at human neuromuscular junctions change with age and in different metabolic conditions using a muscle tissue model.

## Contribution

The study introduces a human skeletal muscle tissue model to investigate age-related and metabolic effects on presynaptic terminal remodeling.

## Key findings

- Presynaptic terminal features like number and size increase with age and correlate with inflammatory and neurotrophic proteins.
- Prolonged in vitro maintenance reproduces age-related presynaptic terminal changes and increases fragmentation.
- Increased presynaptic terminal fragmentation correlates with higher BMI, and fatty acid supplementation partially restores terminal formation.

## Abstract

Neuromuscular junctions (NMJs) connect motor neurons to muscle fibers, enabling electrical-to-chemical signal transmission and sensing of mechanical forces. We employed a previously introduced human skeletal muscle tissue model to study the NMJ presynaptic terminal (PT). Using immunohistochemical approaches, we analyzed PT formation in samples from 12 participants, either immediately after surgery or following 11 days of in vitro maintenance. In immediate postsurgical samples, the number, size, and integrated immunofluorescence intensity of detectable PTs increased with participant age, accompanied by elevated expression of neurotrophic and inflammatory proteins. Moreover, CD80+ and CD206+ macrophages were detected near PTs, suggesting a potential regulatory role in PT formation. Prolonged in vitro maintenance of muscle samples in a quiescent state for 11 days reproduced age-associated PT features and further increased PT spatial expansion and fragmentation. Notably, increased PT fragmentation positively correlated with participant body mass index (BMI), suggesting a possible link between metabolic status and PT remodeling. Consistently, the activation of skeletal muscle metabolism through long-chain fatty acid supplementation partially restored PT formation in vitro. Together, these findings highlight the utility of human skeletal muscle tissue models for investigating NMJ dynamics in pathological contexts and for identifying therapeutic strategies aimed at delaying or preventing neuromuscular decline.

## Linked entities

- **Proteins:** CD80 (CD80 molecule), MRC1 (mannose receptor C-type 1)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** CCL11 (C-C motif chemokine ligand 11) [NCBI Gene 6356] {aka SCYA11}, SV2A (synaptic vesicle glycoprotein 2A) [NCBI Gene 9900] {aka DEE113, SLC22B1, SV2}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, GDNF (glial cell derived neurotrophic factor) [NCBI Gene 2668] {aka ATF, ATF1, ATF2, HFB1-GDNF, HSCR3}, CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348] {aka G0S19-1, LD78, LD78ALPHA, MIP-1-alpha, MIP1A, SCI}, CCL4 (C-C motif chemokine ligand 4) [NCBI Gene 6351] {aka ACT2, AT744.1, G-26, HC21, LAG-1, LAG1}, LTA (lymphotoxin alpha) [NCBI Gene 4049] {aka LT, TNFB, TNFSF1, TNLG1E}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, ITGAM (integrin subunit alpha M) [NCBI Gene 3684] {aka CD11B, CR3A, HNA-4, MAC-1, MAC1A, MO1A}, CD80 (CD80 molecule) [NCBI Gene 941] {aka B7, B7-1, B7.1, BB1, CD28LG, CD28LG1}, IL15 (interleukin 15) [NCBI Gene 3600] {aka IL-15}, IL31 (interleukin 31) [NCBI Gene 386653] {aka IL-31}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, IL7 (interleukin 7) [NCBI Gene 3574] {aka IL-7, IMD130}, Cd80 (CD80 antigen) [NCBI Gene 12519] {aka B71, Cd28l, Ly-53, Ly53, MIC17, TSA1}, NGF (nerve growth factor) [NCBI Gene 4803] {aka Beta-NGF, HSAN5, NGFB}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, CNTF (ciliary neurotrophic factor) [NCBI Gene 1270] {aka HCNTF}, IL1RN (interleukin 1 receptor antagonist) [NCBI Gene 3557] {aka CRMO2, DIRA, ICIL-1RA, IL-1RN, IL-1ra, IL-1ra3}, AGRN (agrin) [NCBI Gene 375790] {aka AGRIN, CMS8, CMSPPD}, CXCL1 (C-X-C motif chemokine ligand 1) [NCBI Gene 2919] {aka FSP, GRO1, GROa, MGSA, MGSA-a, NAP-3}, PIEZO1 (piezo type mechanosensitive ion channel component 1 (Er blood group)) [NCBI Gene 9780] {aka DHS, ER, FAM38A, LMPH3, LMPHM6, Mib}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, BCHE (butyrylcholinesterase) [NCBI Gene 590] {aka BCHED, CHE1, CHE2, E1}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}
- **Diseases:** LEMS (MESH:D015624), cognitive decline (MESH:D003072), frailty (MESH:D000073496), MG (MESH:D009157), NMJ (MESH:D020511), muscle inactivity (MESH:C564765), neuromuscular decline (MESH:D009468), impaired muscle function (MESH:D009135), peripheral neuropathies (MESH:D010523), T2D (MESH:D003924), TRMs (MESH:D055501), age-related decline (MESH:D010024), peripheral nerve injury (MESH:D059348), mitochondrial function (MESH:D028361), sarcopenia (MESH:D055948), muscle atrophy (MESH:D009133), Inflammatory Proteins (MESH:D007249), degenerative changes (MESH:D019636), CMS (MESH:D020294), Trauma (MESH:D014947), ALS (MESH:D000690)
- **Chemicals:** DAPI (MESH:C007293), ethanol (MESH:D000431), formaldehyde (MESH:D005557), PBS (MESH:D007854), Tween-20 (MESH:D011136), Eosin (MESH:D004801), agarose (MESH:D012685), acetylcholine (MESH:D000109), ATP (MESH:D000255), water (MESH:D014867), citrate (MESH:D019343), CO2 (MESH:D002245), FA (MESH:D005227), streptomycin (MESH:D013307), xylene (MESH:D014992), unsaturated FA (MESH:D005231), Hematoxylin (MESH:D006416), penicillin (MESH:D010406), Paraffin (MESH:D010232), Chain Fatty Acids (-), H&amp;E (MESH:D006371)
- **Species:** Bos taurus (bovine, species) [taxon 9913], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12940820/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12940820/full.md

## References

50 references — full list in the complete paper: https://tomesphere.com/paper/PMC12940820/full.md

---
Source: https://tomesphere.com/paper/PMC12940820